alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 10.1


    Exhibit 10.1


    FIRST
      AMENDMENT TO

    RESTRICTED
      STOCK UNIT GRANT

     

     

    WHEREAS,
      on
      April
      7, 2006 (the “Grant Date”), Frontier Oil Corporation (the “Company”) granted to
      the undersigned  
      Restricted Stock Units (“RSUs”) pursuant to the terms of Section 6(e) of the
      Amended and Restated Frontier Oil Corporation 1999 Stock Plan (the “Plan”) and
      the grant agreement with the undersigned dated April 7, 2006 (the
“Award”);

     

    WHEREAS,
      pursuant
      to section 7(iii) of the Plan, the Committee is authorized to make adjustments
      to the terms and conditions of any Award upon the occurrence of certain unusual
      or nonrecurring events and pursuant to section 7(ii) of the Plan, the Committee
      may amend any Award; provided, however, that such amendment shall not reduce
      the
      benefit to the Participant without the consent of the Participant;
      and

     

    WHEREAS,
      in
      connection with the stock dividend with respect to the Common Stock of the
      Company that occurred on June 26, 2006, the Committee has determined that it
      is
      necessary or advisable to amend the Award to clarify the Company’s intent with
      respect to stock dividends;

     

    NOW,
      THEREFORE,
      the
      Award is hereby amended as follows:

     

    Effective
      as of April 7, 2006, the second sentence of Section 5 of the Award shall be
      amended to read as follows:

     

    “As
      of
      each date that stock dividends are paid with respect to Common Stock, to the
      extent that Grantee has any outstanding RSUs credit to his RSU Account, Grantee
      shall have additional RSUs credited to his RSU Account equal to the number
      of
      shares distributed per share of Common Stock, multiplied by the number of RSUs
      credit to Grantee’s RSU Account as of the payment date of such dividend.”


     

    All
      capitalized terms not otherwise defined herein shall have the meanings set
      forth
      in the Plan.

     

    Executed
      this 31st of July, 2006.

     

    “COMPANY”

     

    FRONTIER
      OIL CORPORATION

     

     

    By:
      _____________________________

     

    Printed
      Name: _____________________________

     

    Title:
      _____________________________

     

    Accepted
      and agreed to on this ____ day of ____________, 2006.

     

    “GRANTEE”

     

     

    By:
      _____________________________

     

    Printed
      Name: _____________________________
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 745 Introduced in House (IH)]

109th CONGRESS
  2d Session
H. RES. 745

 Supporting the goals and ideals of Pancreatic Cancer Awareness Month.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 29, 2006

 Mr. Platts submitted the following resolution; which was referred to 
                   the Committee on Government Reform

_______________________________________________________________________

                               RESOLUTION

 
 Supporting the goals and ideals of Pancreatic Cancer Awareness Month.

Whereas over 33,730 people will be diagnosed with pancreatic cancer this year in 
        the United States;
Whereas the mortality rate for pancreatic cancer is 99 percent, the highest of 
        any cancer;
Whereas pancreatic cancer is the 4th most common cause of cancer death in the 
        United States;
Whereas there are no early detection methods and minimal treatment options for 
        pancreatic cancer;
Whereas when symptoms of pancreatic cancer generally present themselves, it is 
        too late for an optimistic prognosis, and the average survival rate of 
        those diagnosed with metastasis disease is only 3 to 6 months;
Whereas pancreatic cancer does not discriminate by age, gender, or race, and 
        only 4 percent of patients survive beyond 5 years;
Whereas the Pancreatic Cancer Action Network (PanCAN), the first national 
        patient advocacy organization serving the pancreatic cancer community, 
        focuses its efforts on public policy, research funding, patient 
        services, and public awareness and education related to developing 
        effective treatments and a cure for pancreatic cancer; and
Whereas the Pancreatic Cancer Action Network has requested that the Congress 
        designate November as Pancreatic Cancer Awareness Month in order to 
        educate communities across the Nation about pancreatic cancer and the 
        need for research funding, early detection methods, effective 
        treatments, and prevention programs: Now, therefore, be it
    Resolved, That the House of Representatives supports the goals and 
ideals of Pancreatic Cancer Awareness Month.
                                 <all>
```
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 05-7514

UNITED STATES OF AMERICA,

Plaintiff - Appellee,

versus

CRAIG A. MURPHY,

Defendant - Appellant.

Appeal from the United States District Court for the Eastern

District of Virginia, at Richmond. Robert E. Payne, District

Judge. (CR-96-66; CA-04-458-3)

Submitted: February 28, 2006 Decided: March 23, 2006

Before WILLIAMS and MOTZ, Circuit Judges, and HAMILTON, Senior

Circuit Judge.

Dismissed by unpublished per curiam opinion.

Craig A. Murphy, Appellant Pro Se. David John Novak, OFFICE OF THE

UNITED STATES ATTORNEY, Richmond, Virginia, for Appellee.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
- 2 -

PER CURIAM:

Craig A. Murphy seeks to appeal the district court’s

orders denying his motion under 28 U.S.C. § 2255 (2000) and denying

his motion to reconsider. The orders are not appealable unless a

circuit justice or judge issues a certificate of appealability. 28

U.S.C. § 2253(c)(1) (2000). 

A certificate of appealability will not issue absent “a

substantial showing of the denial of a constitutional right.” 28

U.S.C. § 2253(c)(2) (2000). A prisoner satisfies this standard by

demonstrating that reasonable jurists would find that his

constitutional claims are debatable and that any dispositive

procedural rulings by the district court are also debatable or

wrong. See Miller-El v. Cockrell, 537 U.S. 322, 336 (2003);

Slack v. McDaniel, 529 U.S. 473, 484 (2000); Rose v. Lee, 252 F.3d

676, 683 (4th Cir. 2001). We have independently reviewed the

record and conclude that Murphy has not made the requisite showing.

Accordingly, we deny a certificate of appealability and

dismiss the appeal. We dispense with oral argument because the

facts and legal contentions are adequately presented in the

materials before the court and argument would not aid the

decisional process.

DISMISSED
§ 1230.30 Collection of samples. Samples for examination by or under the direction and supervision of the Food and Drug Administration shall be collected by: ( a ) An authorized agent in the employ of the Department of Health and Human Services;
( b ) Any officer of any State, Territory, or possession, or of the District of Columbia, authorized by the Secretary of Health and Human Services.
###### Editorial Note on Part 172

#### Editorial Note:

Nomenclature changes to part 172 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

#### § 172.898 Bakers yeast glycan.

Bakers yeast glycan may be safely used in food in accordance with the following conditions:

(a) Bakers yeast glycan is the comminuted, washed, pasteurized, and dried cell walls of the yeast, *Saccharomyces cerevisiae.* It is composed principally of long chain carbohydrates, not less than 85 percent on a dry solids basis. The carbohydrate is composed of glycan and mannan units in approximately a 2:1 ratio.

(b) The additive meets the following specifications on a dry weight basis: Less than 0.4 part per million (ppm) arsenic, 0.13 ppm cadmium, 0.2 ppm lead, 0.05 ppm mercury, 0.09 ppm selenium, and 10 ppm zinc.

(c) The viable microbial content of the finished ingredient is:

(1) Less than 10,000 organisms/gram by aerobic plate count.

(2) Less than 10 yeasts and molds/gram.

(3) Negative for *Salmonella, E. coli,* coagulase positive *Staphylococci, Clostridium perfringens, Clostridium botulinum,* or any other recognized microbial pathogen or any harmful microbial toxin.

(d) The additive is used or intended for use in the following foods when standards of identity established under section 401 of the Act do not preclude such use:

| Use | Limitations |
| --- | --- |
| (1) In salad dressings as an emulsifier and emulsifier salt as defined in § 170.3(o)(8) of this chapter, stabilizer and thickener as defined in § 170.3(o)(28) of this chapter, or texturizer as defined in § 170.3(o)(32) of this chapter | Not to exceed a concentration of 5 percent of the finished salad dressing. |
| (2) In frozen dessert analogs as a stabilizer and thickener as defined in § 170.3(o)(28) of this chapter, or texturizer as defined in § 170.3(o)(32) of this chapter | In an amount not to exceed good manufacturing practice. |
| (3) In sour cream analogs as a stabilizer and thickener as defined in § 170.3(o)(28) of this chapter, or texturizer as defined in § 170.3(o)(32) of this chapter | Do. |
| (4) In cheese spread analogs as a stabilizer and thickener as defined in § 170.3(o)(28) of this chapter, or texturizer as defined in § 170.3(o)(32) of this chapter | Do. |
| (5) In cheese-flavored and sour cream-flavored snack dips as a stabilizer and thickener as defined in § 170.3(o)(28) of this chapter, or texturizer as defined in § 170.3(o)(32) of this chapter | Do. |

(e) The label and labeling of the ingredient shall bear adequate directions to assure that use of the ingredient complies with this regulation.

[42 FR 14491, Mar. 15, 1977, as amended at 45 FR 58836, Sept. 5, 1980]
Editorial Note on Part 173
Editorial Note: Nomenclature changes to part 173 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; and 81 FR 49896, July 29, 2016.

§ 173.140 Esterase-lipase derived from *Mucor miehei.* Esterase-lipase enzyme, consisting of enzyme derived from *Mucor miehei* var. *Cooney et Emerson* by a pure culture fermentation process, with maltodextrin or sweet whey as a carrier, may be safely used in food in accordance with the following conditions: ( a ) *Mucor miehei* var. *Cooney et Emerson* is classified as follows: Class, Phycomycetes; subclass, Zygomycetes; order, Mucorales; family, Mucoraceae; genus, *Mucor;* species, *miehei;* variety *Cooney et Emerson.*
( b ) The strain of *Mucor miehei* var. *Cooney et Emerson* is nonpathogenic and nontoxic in man or other animals.
( c ) The enzyme is produced by a process which completely removes the organism *Mucor miehei* var. *Cooney et Emerson* from the esterase-lipase.
( d ) The enzyme is used as a flavor enhancer as defined in § 170.3(o)(12).
( e ) The enzyme is used at levels not to exceed current good manufacturing practice in the following food categories: cheeses as defined in § 170.3(n)(5) of this chapter; fat and oils as defined in § 170.(3)(n)(12) of this chapter; and milk products as defined in § 170.(3)(n)(31) of this chapter. Use of this food ingredient is limited to nonstandarized foods and those foods for which the relevant standards of identity permit such use.
( f ) The enzyme is used in the minimum amount required to produce its limited technical effect.
[47 FR 28090, June 29, 1982; 48 FR 2748, Jan. 21, 1983]
§ 1301.24 Exemption of law enforcement officials. ( a ) The requirement of registration is waived for the following persons in the circumstances described in this section: ( 1 ) Any officer or employee of the Administration, any customs officer, any officer or employee of the U.S. Food and Drug Administration, and any other Federal or Insular officer who is lawfully engaged in the enforcement of any Federal law relating to controlled substances, drugs, or customs, and is duly authorized to possess or to import or export controlled substances in the course of his/her official duties; and
( 2 ) Any officer or employee of any State, or any political subdivision or agency thereof, who is engaged in the enforcement of any State or local law relating to controlled substances and is duly authorized to possess controlled substances in the course of his/her official duties.
( b ) Any official exempted by this section may, when acting in the course of his/her official duties, procure any controlled substance in the course of an inspection, or in the course of any criminal investigation involving the person from whom the substance was procured, and may possess any controlled substance and distribute any such substance to any other official who is also exempted by this section and acting in the course of his/her official duties.
( c ) In order to enable law enforcement agency laboratories, including laboratories of the Administration, to obtain and transfer controlled substances for use as standards in chemical analysis, such laboratories shall obtain annually a registration to conduct chemical analysis. Such laboratories shall be exempted from payment of a fee for registration. Laboratory personnel, when acting in the scope of their official duties, are deemed to be officials exempted by this section and within the activity described in section 515(d) of the Act (21 U.S.C. 885(d)). For purposes of this paragraph, laboratory activities shall not include field or other preliminary chemical tests by officials exempted by this section.
( d ) In addition to the activities authorized under a registration to conduct chemical analysis pursuant to § 1301.13(e)(1)(ix), laboratories of the Administration shall be authorized to manufacture or import controlled substances for any lawful purpose, to distribute or export such substances to any person, and to import and export such substances in emergencies without regard to the requirements of part 1312 of this chapter if a report concerning the importation or exportation is made to the Drug Operations Section of the Administration within 30 days of such importation or exportation.
[62 FR 13951, Mar. 24, 1997, as amended at 81 FR 97019, Dec. 30, 2016; 87 FR 66955, Nov. 7, 2022]
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 649 Introduced in House (IH)]

<DOC>

115th CONGRESS
  1st Session
H. RES. 649

 Expressing the sense of the House of Representatives with respect to 
                             Marcus Garvey.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            December 7, 2017

   Ms. Clarke of New York (for herself and Mr. Evans) submitted the 
   following resolution; which was referred to the Committee on the 
                               Judiciary

_______________________________________________________________________

                               RESOLUTION

 
 Expressing the sense of the House of Representatives with respect to 
                             Marcus Garvey.

Whereas Marcus Mosiah Garvey, Jamaica's first national hero, was born in St. 
        Ann's Bay, Jamaica, on August 17, 1887, and emigrated to the United 
        States where he founded the Universal Negro Improvement Association;
Whereas Marcus Garvey was the father of the largest African-American movement 
        for human rights and economic self-sufficiency of all time, attracting 
        millions of followers in the United States, the Caribbean, Latin 
        America, Africa, and Europe;
Whereas Marcus Garvey's philosophy inspired some of the world's great Black 
        leaders;
Whereas leading a movement for economic independence among Black Americans, 
        Marcus Garvey became the target of surveillance and harassment by United 
        States Government law enforcement agencies;
Whereas Marcus Garvey was prosecuted and convicted of mail fraud, imprisoned, 
        and later, deported to Jamaica;
Whereas the case against Marcus Garvey was politically motivated, the charges 
        unsubstantiated, and his conviction unjust;
Whereas millions of petitioners have appealed for his exoneration;
Whereas Marcus Garvey is recognized as a national hero in his native Jamaica, 
        and as a towering figure in nations around the world; and
Whereas Marcus Garvey's life and contributions to the United States should be 
        recognized and appropriate steps taken to restore his name and 
        reputation in this country: Now, therefore, be it
    Resolved, That it is the sense of the House of Representatives 
that--
            (1) Marcus Garvey was innocent of the charges brought 
        against him by the United States Government;
            (2) Marcus Garvey was and should be recognized 
        internationally as a leader and thinker in the struggle for 
        human rights; and
            (3) the President should take appropriate measures within 
        his power to clear Marcus Garvey's good name.
                                 <all>
```
```

[Federal Register Volume 75, Number 34 (Monday, February 22, 2010)]
[Notices]
[Pages 7570-7571]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3376]

-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Navy

Notice of Public Hearings for the Draft Environmental Impact 
Statement for the Silver Strand Training Complex, San Diego, CA; 
Correction

AGENCY: Department of Navy, DoD.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Department of the Navy published a document in the Federal 
Register (75 FR 4537) of January 28, 2010, concerning public hearings 
on a Draft Environmental Impact Statement for the Silver Strand 
Training Complex, San Diego, CA. The document contained incorrect 
dates.

FOR FURTHER INFORMATION CONTACT: Naval Facilities Engineering Command 
Southwest, Attention: Mr. Kent Randall, SSTC EIS Project Manager, 1220 
Pacific Highway, Building 1, 5th Floor, San Diego, CA, 92132; or http://www.silverstrandtrainingcomplexeis.com.

Correction

    In the Federal Register (75 FR 4537) of January 28, 2010, on page 
4537, in the third column, correct Dates and Addresses caption to read:

[[Page 7571]]

    Dates and Addresses: Two public hearings will be held in San 
Diego County, CA to receive oral and written comments on the DEIS. 
All meetings will start with an open house session from 4 p.m. to 6 
p.m., followed by a presentation and formal public comment period 
from 6 p.m. to 7:30 p.m. Public hearings will be held on the 
following dates and at the following locations:

1. Tuesday, February 23, 2010, at the Imperial Beach City Hall 
Community Room, 825 Imperial Beach Boulevard, Imperial Beach, CA; 
and
2. Wednesday, February 24, 2010, at the Coronado Community Center, 
Nautilus Banquet Room, 1845 Strand Way, Coronado, CA.

    Dated: February 5, 2010.
A.M. Vallandingam
Lieutenant Commander, Office of the Judge Advocate General, U.S. Navy, 
Federal Register Liaison Officer.
[FR Doc. 2010-3376 Filed 2-19-10; 8:45 am]
BILLING CODE 3810-FF-P
```
[Nos. 15875-6-III; 16445-4-III.

Division Three.

December 2, 1997.]

#### The State of Washington, *Respondent,*v. James C. Miller, *Appellant. In the Matter of the Personal Restraint of*James Calvin Miller, *Petitioner.*

Appeal from a judgment of the Superior Court for Asotin County, No. 96-1-00035-5, John M. Lyden, J., entered June 7, 1996, together with a petition for relief from *1032personal restraint. Judgement *reversed*and petition *granted*by unpublished opinion per Burchard, J. Pro Tern., concurred in by Sweeney, C.J., and Kurtz, J. Now published at 89 Wn. App. 364.
[Federal Register Volume 76, Number 3 (Wednesday, January 5, 2011)]
[Notices]
[Pages 574-575]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-33321]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of a meeting of the 
National Cancer Institute Clinical Trials and Translational Research 
Advisory Committee.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should

[[Page 575]]

notify the Contact Person listed below in advance of the meeting.

    Name of Committee: National Cancer Institute Clinical Trials and 
Translational Research Advisory Committee.
    Date: March 3, 2011.
    Time: 9 a.m. to 4 p.m.
    Agenda: Strategic Discussion of NCI's Clinical and Translational 
Research Programs.
    Place: National Institutes of Health, Building 31, 31 Center 
Drive, C-wing, 6th Floor, Conference Rooms, Bethesda, MD 20892.
    Contact Person: Sheila A. Prindiville, MD, MPH, Director, 
Coordinating Center for Clinical Trials, Office of the Director, 
National Cancer Institute, National Institutes of Health, 6120 
Executive Blvd., 3rd Floor Suite, Bethesda, MD 20892, 301-451-5048, 
<a href="/cdn-cgi/l/email-protection#acdcdec5c2c8c5dadfecc1cdc5c082c2c5c482cbc3da"><span class="__cf_email__" data-cfemail="afdfddc6c1cbc6d9dcefc2cec6c381c1c6c781c8c0d9">[email protected]</span></a>.
    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    In the interest of security, NIH has instituted stringent 
procedures for entrance onto the NIH campus. All visitor vehicles, 
including taxicabs, hotel, and airport shuttles will be inspected 
before being allowed on campus. Visitors will be asked to show one 
form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their 
visit.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: December 28, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-33321 Filed 1-4-11; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>